Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

BACKGROUND: BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment of moderate or severe opioid use disorder. The primary objective of this phase III study was to assess the lon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Psychopharmacol
Hauptverfasser: Andorn, Anne C., Haight, Barbara R., Shinde, Sunita, Fudala, Paul J., Zhao, Yue, Heidbreder, Christian, Learned, Susan M., Fox, Norma Lynn, Nadipelli, Vijay R., Hassman, David, Rutrick, Daniel
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2020
Schlagworte:
Original Contributions
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188268/
https://ncbi.nlm.nih.gov/pubmed/32282418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000001195
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge